{"DataElement":{"publicId":"6002713","version":"1","preferredName":"Performed Specimen Collection Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation that are related to assessments of samples for subsequent analysis, as outlined in the study protocol.","longName":"SPEC_ASSESS_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6002712","version":"1","preferredName":"Performed Specimen Collection Assessment Clinical Trial Eligibility Criteria","preferredDefinition":"The completed action of gathering samples that may be used for subsequent analysis._The final result of a determination of the value, significance, or extent of._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"6002710v1.0:5582954v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"6002710","version":"1","preferredName":"Performed Specimen Collection","preferredDefinition":"The completed action of gathering samples that may be used for subsequent analysis.","longName":"C93435","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Performed Specimen Collection","conceptCode":"C93435","definition":"The completed action of gathering samples that may be used for subsequent analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5CF2F2-D007-516F-E053-F662850A2D22","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5582954","version":"1","preferredName":"Assessment Clinical Trial Eligibility Criteria","preferredDefinition":"The final result of a determination of the value, significance, or extent of.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C25217:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4288623F-37E1-1850-E053-F662850A470C","latestVersionIndicator":"Yes","beginDate":"2016-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-30","modifiedBy":"ONEDATA","dateModified":"2016-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5CF2F2-D015-516F-E053-F662850A2D22","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-12","modifiedBy":"TAYLORT","dateModified":"2018-02-06","changeDescription":"10/12/17 tt 10130.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876423","version":"1","longName":"Consents & Contraceptive Guidelines","context":"Theradex"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"If available, has archival ti","type":"Preferred Question Text","description":"If available, has archival tissue (block or minimum 10 slides) been requested for molecular characterization, e.g. detection of somatic mutations and/or candidate biomarkers of response?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Are formalin-fixed, paraffin-embedded (FFPE) archival tumor specimens available at the study site?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has tissue (biopsy or archival) and blood been obtained for shipment to ETCTN Biorepository and UC Davis Cancer Center?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Has baseline (pre-treatment) blood and tissue been collected for shipment to Washington University and ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Will a tumor specimen from relapsed metastatic or locally advanced disease (if applicable) be collected and submitted following registration?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Has baseline (pre-treatment) tumor tissue been collected for shipment to ETCTN Biorepository/MoCha lab?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Has baseline (pre-treatment) tissue been collected for shipment to Washington University and ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Have pre-treatment samples, after informed consent and within 14 days of cycle 1 day 1, been obtained for sending to the ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Are screening (pre-treatment) specimens available for submission to ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Is archival specimen available for submission to ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Have bone marrow and/or peripheral blood specimens been submitted for correlative studies as outlined in Section 9?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Are samples collected prior to C1D1 being sent to ETCTN Biorepository, CLIA-Certified Lab, Eutropics Pharmaceuticals, Inc. and JHU SKCCC Analytical Pharmacology Core Lab?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Have pre-treatment specimens been obtained for sending to PADIS, UC Davis, University of Pittsburgh, and Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Have pre-treatment specimens been obtained for sending to ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Are archival tumor, fresh tumor biopsy (optional) and germline blood available for submission to Biorepository for CIMAC?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Have pre-treatment samples, after informed consent and within 30 days of inclusion, been obtained for sending to the ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"If applicable (not required for patients in Part 1, optional in Part 2), is archival specimen available for submission to ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Is archival or fresh pre-treatment biopsy (mandatory for radiation biopsy cohort A in phase 2) available for submission to ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Have pre-treatment samples, after informed consent been obtained for PK sampling or PD biomarkers?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Will archival tissue or fresh biopsy be collected for submission to ETCTN biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"If available, has archival specimen been submitted to the ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"If patient was treated on ARM B, has the patient provided a tumor biopsy at the time of progression prior to cross over?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Will archival tissue and blood be sent to the ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Has tissue (biopsy or archival) been obtained for shipment to the ETCTN Biorepository, Princess Margaret Cancer Center and or CIMAC?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Has archival tissue been collected within 6 months prior to registration and consist of metastatic tumor tissue for submission to the ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Have baseline samples (bone marrow & blood) been collected at screening?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Have archival tumor specimen been obtained OR will baseline tumor biopsy specimen be obtained for submission to UNC-Hospital or the ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Is archival tissue specimen available and will be submitted to ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Will tumor tissue be collected pre-study treatment at the time of fiducial placement?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Is archival tumor tissue available for submission to MD Anderson or local CLIA-Certified Laboratory (optional for dose escalation, mandatory for dose expansion)?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Have baseline samples (bone marrow & blood) been collected at screening?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Have archival tissue been collected or will new biopsy be collected for submission to the ETCTN biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Have/will samples be collected for submission to Ohio State University CLIA-certified lab, Molecular Sequencing Lab and Ohio State Leukemia Tissue Bank?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Was archival tumor tissue submitted as a baseline specimen within 3 months prior to patient registration?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Have (will) bone marrow samples been collected for testing of TP53, H3K27me3 MTF2 and Nuclear p53?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"If available, will pre-chemotherapy and post-chemotherapy surgical resection specimens be submitted to the ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Has baseline (pre-treatment) tumor tissue been collected for shipment to ETCTN Biorepository, University of Wisconsin, Asuragen and QPS?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"If the patient is being enrolled at progression, is there existing archival material and does the archival material contain the cancer type for which the patient is being enrolled?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Is archival tissue available for submission to ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"For Phase 1, patient agrees to participate in Pharmacokinetic sampling; For Phase 2, patient agrees to have tumor tissue collected pre-study treatment, at the time of fiducial placement?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Does patient have adequate primary tumor volume, as determined by imaging (e.g., CT, ultrasound, MRI) at eligibility screening, to accommodate research specimen collections in addition to clinical pathology evaluation?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"Has archival sample (all cohorts, dose escalation and expansion) been obtained for submission to the ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"Has archival sample been obtained for submission to the ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"Has archival tissue been obtained or is a baseline biopsy planned for specimen submission to the ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Have pre-treatment samples, after informed consent and within 14 days prior to start of protocol therapy, been obtained for sending to the ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"Will archival or baseline biopsy specimens be obtained for submission to the NCI laboratory of pathology or Laboratory of Andrew Warner?","url":null,"context":"Theradex"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"Have pre-study bone marrow biopsy and blood sample for biomarkers been collected for submission?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"Have baseline samples (tissue and blood) been collected for shipment to Payton Laboratory and ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Will archival or baseline biopsy specimens be obtained for submission to the ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"Will archival tumor sample or pre-treatment biopsy specimens be obtained for submission to the CITN Central Immune Monitoring Lab (CIML)?","url":null,"context":"Theradex"},{"name":"Theradex - 54","type":"Alternate Question Text","description":"Will baseline bone marrow aspirate and bone marrow core biopsy be obtained for submission to EET Biobank?","url":null,"context":"Theradex"},{"name":"Theradex - 55","type":"Alternate Question Text","description":"Is archival tissue block or slides available for submission to the EET Biobank?","url":null,"context":"Theradex"},{"name":"Theradex - 56","type":"Alternate Question Text","description":"Has a bone marrow aspirate and biopsy been performed, and tissue collected?","url":null,"context":"Theradex"},{"name":"Theradex - 57","type":"Alternate Question Text","description":"If patient is in the dose expansion cohort, will tissue and blood be sent to EET Biobank within 15 days of course 1 day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 60","type":"Alternate Question Text","description":"Is patient able to provide an archival tissue specimen (block or slides) for submission to the EET Biobank?","url":null,"context":"Theradex"},{"name":"Theradex - 58","type":"Alternate Question Text","description":"If archival tissue is being submitted are the following criteria met: tissue was collected within 3 months prior to registration and patient has not received any intervening therapy for their cancer since the collection of the tumor sample?","url":null,"context":"Theradex"},{"name":"Theradex - 61","type":"Alternate Question Text","description":"Will tissue (fresh or frozen) or blood specimens be obtained for submission to the EET Biobank or Chapkin laboratory, Texas A&M University?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"Will enrolling site perform PD-L1 testing on tumor biopsy per institutional protocol (local testing or tissue sent to outside laboratory for PD-L1 IHC 22C3 pharmDx)?","url":null,"context":"Theradex"},{"name":"Theradex - 62","type":"Alternate Question Text","description":"Has archival tissue been collected within 12 months prior to registration and consist of metastatic tumor for submission to the ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Will tissue sample be submitted for analysis of PD-LI status?","url":null,"context":"Theradex"},{"name":"Theradex - 59","type":"Alternate Question Text","description":"If the patient is currently on an Appendix A therapy (clinical scenarios c and d), is there existing archival material that meets the following requirements?","url":null,"context":"Theradex"},{"name":"Theradex - 63","type":"Alternate Question Text","description":"Will archival, or baseline biopsy or baseline blood specimen be obtained for submission to the ETCTN Biorepository?","url":null,"context":"Theradex"},{"name":"Theradex - 64","type":"Alternate Question Text","description":"If patient is enrolled in the expansion phase, has pre-enrollment tissue been submitted to local lab or Laboratory of Personalized Genomic Medicine, Columbia University Medical Center?","url":null,"context":"Theradex"},{"name":"Theradex - 65","type":"Alternate Question Text","description":"Is Formalin-fixed paraffin-embedded (FFPE) tumor rich tissue block or slides available for submission to Biobank?","url":null,"context":"Theradex"},{"name":"Theradex - 66","type":"Alternate Question Text","description":"If the patient is currently on an Appendix A therapy (clinical scenarios c and d), is there existing archival material that meets the following requirements: i. Contains the cancer type for which the patient is being enrolled AND ii. Collected less than or equal to 5 years prior to initiation of a therapy listed in Appendix A AND iii. Contains at least a surface area of 5 mm2 and optimum surface area of 25 mm2 or 3-5mL cryopreserved bone marrow aspirate to yield 200 million bone marrow mononuclear cells, AND iv. The patient has received no more than one line of intervening standard of care therapy from the date of collection of the archival material to starting an Appendix A therapy.","url":null,"context":"Theradex"},{"name":"Theradex - 67","type":"Alternate Question Text","description":"Is adequate archival specimen obtained within 8 weeks of Step 1 Registration available for submission to ETCTN Biorepository OR patient has sufficient tumor and is willing to undergo an endometrial pipelle biopsy prior to beginning of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 68","type":"Alternate Question Text","description":"Is patient willing to undergo a mandatory tumor biopsy on treatment and able to provide an archival tissue specimen (block or slides) for submission to the EET Biobank?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5C0788-121A-6E69-E053-F662850A3416","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-12","modifiedBy":"SOKKERL","dateModified":"2024-01-24","changeDescription":"2020-7-27 AQT added for protocol 10389. AK 10/12/17 tt 10130.","administrativeNotes":"2023.8.9 AQT added per ticket request CADSR0002718. ak 2023.4.5 AQT added per ticket request CADSR0002271. ak","unresolvedIssues":null,"deletedIndicator":"No"}}